Severe Hepatopathy in National Wilms Tumor Studies 3-5: Prevalence, Clinical Features, and Outcomes after Reintroduction of Chemotherapy

Natanja Oosterom; Saskia L.M. Gooskens; Lindsay A. Renfro; Elizabeth J. Perlman; Marry M. Van Den Heuvel-Eibrink; Thomas E. Hamilton; Daniel M. Green; Paul E. Grundy; Najat C. Daw; James I. Geller; Jeffrey S. Dome; Conrad V. Fernandez; Elizabeth A. Mullen

doi:10.1200/JCO.22.02555

Severe Hepatopathy in National Wilms Tumor Studies 3-5: Prevalence, Clinical Features, and Outcomes after Reintroduction of Chemotherapy

Natanja Oosterom, Saskia L.M. Gooskens, Lindsay A. Renfro, Elizabeth J. Perlman, Marry M. Van Den Heuvel-Eibrink, Thomas E. Hamilton, Daniel M. Green, Paul E. Grundy, Najat C. Daw, James I. Geller, Jeffrey S. Dome, Conrad V. Fernandez, Elizabeth A. Mullen

Immunology and Microbiology

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	4247-4256
Number of pages	10
Journal	Journal of Clinical Oncology
Volume	41
Issue number	26
DOIs	https://doi.org/10.1200/JCO.22.02555
Publication status	Published - Sept 10 2023

ASJC Scopus Subject Areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1200/JCO.22.02555

Cite this

Oosterom, N., Gooskens, S. L. M., Renfro, L. A., Perlman, E. J., Van Den Heuvel-Eibrink, M. M., Hamilton, T. E., Green, D. M., Grundy, P. E., Daw, N. C., Geller, J. I., Dome, J. S., Fernandez, C. V., & Mullen, E. A. (2023). Severe Hepatopathy in National Wilms Tumor Studies 3-5: Prevalence, Clinical Features, and Outcomes after Reintroduction of Chemotherapy. Journal of Clinical Oncology, 41(26), 4247-4256. https://doi.org/10.1200/JCO.22.02555

Oosterom, N, Gooskens, SLM, Renfro, LA, Perlman, EJ, Van Den Heuvel-Eibrink, MM, Hamilton, TE, Green, DM, Grundy, PE, Daw, NC, Geller, JI, Dome, JS, Fernandez, CV & Mullen, EA 2023, 'Severe Hepatopathy in National Wilms Tumor Studies 3-5: Prevalence, Clinical Features, and Outcomes after Reintroduction of Chemotherapy', Journal of Clinical Oncology, vol. 41, no. 26, pp. 4247-4256. https://doi.org/10.1200/JCO.22.02555

@article{2e996b63d14043dab41c0730f8039ad4,

title = "Severe Hepatopathy in National Wilms Tumor Studies 3-5: Prevalence, Clinical Features, and Outcomes after Reintroduction of Chemotherapy",

author = "Natanja Oosterom and Gooskens, {Saskia L.M.} and Renfro, {Lindsay A.} and Perlman, {Elizabeth J.} and {Van Den Heuvel-Eibrink}, {Marry M.} and Hamilton, {Thomas E.} and Green, {Daniel M.} and Grundy, {Paul E.} and Daw, {Najat C.} and Geller, {James I.} and Dome, {Jeffrey S.} and Fernandez, {Conrad V.} and Mullen, {Elizabeth A.}",

note = "Publisher Copyright: {\textcopyright} American Society of Clinical Oncology.",

year = "2023",

month = sep,

day = "10",

doi = "10.1200/JCO.22.02555",

language = "English",

volume = "41",

pages = "4247--4256",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "26",

}

TY - JOUR

T1 - Severe Hepatopathy in National Wilms Tumor Studies 3-5

T2 - Prevalence, Clinical Features, and Outcomes after Reintroduction of Chemotherapy

AU - Oosterom, Natanja

AU - Gooskens, Saskia L.M.

AU - Renfro, Lindsay A.

AU - Perlman, Elizabeth J.

AU - Van Den Heuvel-Eibrink, Marry M.

AU - Hamilton, Thomas E.

AU - Green, Daniel M.

AU - Grundy, Paul E.

AU - Daw, Najat C.

AU - Geller, James I.

AU - Dome, Jeffrey S.

AU - Fernandez, Conrad V.

AU - Mullen, Elizabeth A.

PY - 2023/9/10

Y1 - 2023/9/10

UR - http://www.scopus.com/inward/record.url?scp=85170111905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85170111905&partnerID=8YFLogxK

U2 - 10.1200/JCO.22.02555

DO - 10.1200/JCO.22.02555

M3 - Article

C2 - 37343199

AN - SCOPUS:85170111905

SN - 0732-183X

VL - 41

SP - 4247

EP - 4256

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 26

ER -

Severe Hepatopathy in National Wilms Tumor Studies 3-5: Prevalence, Clinical Features, and Outcomes after Reintroduction of Chemotherapy

ASJC Scopus Subject Areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this